SSY Group (HKG:2005) has received approval for the production and registration of Voriconazole for Oral Suspension from China's National Medical Products Administration, according to a Friday bourse filing.
Classified as a type 4 chemical drug, the product has also passed the consistency evaluation.
Voriconazole is indicated to treat various fungal infections, such as invasive aspergillosis, candidemia, and infections caused by Scedosporium and Fusarium.
Additionally, it is prescribed for preventing invasive fungal infections in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.